AOC3
Amine oxidase [copper-containing] 3
As of the edition of 20 October 2026, AOC3 (amine oxidase [copper-containing] 3, UniProt Q16853) has 3 drugs tested at it and 3 companies on the list, 2 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- Q16853
- How well studied
- Chemical tools exist; no approved drug acts on it
- Where it sits in the cell
- At a membrane
- Solved structures
- 11
- Disease areas
- Digestive system; Bones, joints and muscles; Eye; Heart and blood vessels; Hormones; Immune system; Pregnancy and women's health; Skin and connective tissue
- Registered trials of its drugs
- 14
Drugs at this target
| Status | Count |
|---|---|
| Went quiet | 2 |
| Status not established | 1 |
| Total | 3 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| BI 1467335 | Went quiet | Phase 2 | none listed |
| Timolumab | Went quiet | Phase 2 | none listed |
| TT-01025-CL | Status not established | Phase 1 | none listed |
3 of 3 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 2 |
| Undetermined | 1 |
| Total on the list | 3 |
| Company | Route |
|---|---|
| Boehringer Ingelheim | Route A |
| Biotie Therapies | Route A |
The other 1 company at AOC3
In the product3 companies in all; 1 is not named here, and no score is.
See the 3 companies at AOC3, ranked, with the facts behind eachRequest access. Nothing is shown until you do.